Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acrocyanosis induced by interferon alpha(2a)

A Campo-Voegeli1, T Estrach, R M Marti

  • 1Department of Dermatology, Hospital Clinic i Provincial de Barcelona, España.

Dermatology (Basel, Switzerland)
|June 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refractory Dermatomyositis Treated With Anifrolumab: Clinical Response and Dynamics of Type-I Interferon Signature.

Actas dermo-sifiliograficas·2026
Same author

Cutaneous Melanoma: Association of Histopathological Subtypes and Breslow Thickness With Occupation and Residence in an Observational Study of 2486 Patients.

Actas dermo-sifiliograficas·2026
Same author

Clinical Outcomes of Intra-Abdominal Candidiasis by Initial Antifungal Therapy.

Mycoses·2026
Same author

RF-Biological Treatments in Familial Benign Pemphigus or Hailey-Hailey Disease.

Actas dermo-sifiliograficas·2025
Same author

RF-New Treatments in Dermatomyositis: Present and Future.

Actas dermo-sifiliograficas·2025
Same author

Clinical, Histopathological, and Therapeutic Features in Lupus Erythematosus Tumidus: A Retrospective Study.

Actas dermo-sifiliograficas·2025
Same journal

Survey on Difficult to Treat Tinea: A Sub-Saharan Africa Snapshot.

Dermatology (Basel, Switzerland)·2026
Same journal

Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.

Dermatology (Basel, Switzerland)·2026
Same journal

Clinical Insights and Prognostic Factors in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Cohort Study.

Dermatology (Basel, Switzerland)·2026
Same journal

Descriptive Analysis of DRESS Reports from EudraVigilance and DRESS Cases from the RegiSCAR-project.

Dermatology (Basel, Switzerland)·2026
Same journal

The Role of the Vagus Nerve and Its Stimulation in Modulating Inflammatory Skin Diseases and Other Dermatologic Conditions: From Mechanisms to Therapeutics.

Dermatology (Basel, Switzerland)·2026
Same journal

Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors.

Dermatology (Basel, Switzerland)·2026
See all related articles

A woman experienced acrocyanosis during interferon alpha-2a treatment for mycosis fungoides. This side effect, linked to elevated antinuclear antibody titers, highlights potential autoimmune risks of interferon therapy.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Mycosis fungoides is a type of cutaneous T-cell lymphoma.
  • Interferon therapy is used for certain cancers and viral infections.
  • Autoimmune side effects are known complications of long-term interferon treatment.

Observation:

  • A 56-year-old woman with mycosis fungoides developed acrocyanosis.
  • Acrocyanosis recurred upon initiation of interferon alpha-2a and resolved upon discontinuation.
  • Immunological studies revealed elevated antinuclear antibody (ANA) titers and immune complexes during acrocyanosis.

Findings:

  • This case presents acrocyanosis as a previously undescribed side effect of interferon alpha-2a.
  • The patient's symptoms correlated with immunological markers of autoimmunity.

Related Experiment Videos

  • Interferon-induced autoimmunity may manifest in various ways, including peripheral vascular changes.

    • Implications:

    • Clinicians should consider acrocyanosis as a potential adverse effect of interferon alpha-2a, particularly in patients with underlying autoimmune risk factors.
    • Further research is warranted to elucidate the mechanisms linking interferon therapy to acrocyanosis and other autoimmune phenomena.
    • This finding expands the spectrum of known interferon-related side effects and emphasizes the importance of vigilant monitoring for autoimmune complications during treatment.